Nanocarry Therapeutics

Executive Summary

Nanocarry Therapeutics is an Israeli preclinical biotech pioneering a nano-engineered platform that uses gold nanoparticles to deliver biologics across the blood-brain barrier. Their technology addresses a critical bottleneck in neuro-oncology and CNS drug development by enabling high-efficiency transport of antibodies and macromolecules into the brain. The company is initially targeting brain metastases from breast and lung cancer, with potential expansion to other CNS diseases. Founded in 2020 and backed by $5 million in funding, Nanocarries is advancing its lead candidate through preclinical studies. The platform's unique mechanism could offer a much-needed solution for patients with limited treatment options, positioning the company for significant value creation if proof-of-concept data are positive.

Upcoming Catalysts (preview)

• Q1 2027Lead candidate IND-enabling studies completion60% success
• Q4 2026Initial in vivo efficacy data in brain metastasis models70% success
• Q2 2027Strategic partnership or licensing deal for CNS platform40% success